Souderton, PA, United States of America

Decheng Ma

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2017-2020

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Decheng Ma: Innovator in Pharmaceutical Compositions

Introduction

Decheng Ma is a notable inventor based in the United States, recognized for his contributions to the field of pharmaceuticals. His work primarily focuses on the development of solid pharmaceutical compositions that play a crucial role in the treatment of HIV.

Latest Patents

One of his significant patents is titled "Solid Pharmaceutical Compositions Containing An Integrase Inhibitor." This patent describes compressed tablets for oral administration containing raltegravir, which is presented in the form of a pharmaceutically acceptable salt. The formulation includes an intragranular component that consists of an effective amount of an alkali metal salt of raltegravir, a first superdisintegrant, and a binder. Additionally, the extragranular component comprises a second superdisintegrant, a filler, and a lubricant. The patent also outlines methods for preparing these tablets and their use, optionally in combination with other anti-HIV agents, for inhibiting HIV integrase and treating or preventing HIV infection and AIDS.

Career Highlights

Throughout his career, Decheng Ma has focused on innovative solutions in the pharmaceutical industry. His work has contributed to advancements in drug formulations that enhance the efficacy of treatments for HIV.

Collaborations

Decheng Ma has collaborated with Majid Mahjour, working together to advance their research and development efforts in the pharmaceutical sector.

Conclusion

Decheng Ma's contributions to pharmaceutical compositions, particularly in the area of HIV treatment, highlight his innovative spirit and dedication to improving healthcare solutions. His work continues to influence the field and offers hope for better treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…